Evidence map›Paper›PMID 28129499›Full record

Trial reportThe Journal of clinical psychiatry2017

Toward National Estimates of Effectiveness of Treatment for Substance Use.

Carlos Blanco, Aimee N Campbell, Melanie M Wall, Mark Olfson, Shuai Wang, Edward V Nunes

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The Journal of clinical psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Carlos BlancoNational Institute on Drug Abuse, Rockville, Maryland, USA.
Aimee N CampbellDepartment of Psychiatry, New York State Psychiatric Institute/Columbia University, New York, New York, USA.
Melanie M WallDepartment of Psychiatry, New York State Psychiatric Institute/Columbia University, New York, New York, USA.
Mark OlfsonDepartment of Psychiatry, New York State Psychiatric Institute/Columbia University, 1051 Riverside Dr, Unit 24, New York, NY 10032. mo49@cumc.columbia.edu.
Shuai WangDepartment of Psychiatry, New York State Psychiatric Institute/Columbia University, New York, New York, USA.
Edward V NunesDepartment of Psychiatry, New York State Psychiatric Institute/Columbia University, New York, New York, USA.
New York Psychoanalytic Society and Institute · USColumbia University · USNational Institute on Drug Abuse · US

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUPU10DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 1999 to 2015
$25.2M
Concept ProjectU10DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI TRIVEDI, MADHUKAR H. · 2005 to 2015
$22.6M
Establishing Moderators/Biosignatures of Antidepressant Response- Clinical CareU01MH092221 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI TRIVEDI, MADHUKAR H. · 2010 to 2015
$9.7M
Improving the Effectiveness of Treatment for Depression in HispanicsR01MH076051 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI BLANCO, CARLOS · 2008 to 2012
$2.8M
NIDA NIH HHS K02 DA023200NIDA NIH HHS K24 DA022412NIDA NIH HHS U10 DA013034NIDA NIH HHS U10 DA013035NIDA NIH HHS U10 DA013714NIDA NIH HHS U10 DA013720NIDA NIH HHS U10 DA013732NIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA015831NIDA NIH HHS U10 DA020024NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA020024NIMH NIH HHS R01 MH076051NIMH NIH HHS R01 MH082773NIMH NIH HHS U01 MH061562NIMH NIH HHS U01 MH092221
6 · The paper itself

Abstract

objectiveTo estimate how results would have varied if a substance abuse clinical trial had been conducted with nationally representative adults with substance use and with representative adults receiving substance use treatment.

methodsResults were analyzed from a multisite clinical trial comparing the effectiveness of the Therapeutic Education System to treatment as usual for outpatient addiction treatment (n = 507). Patients were recruited between June 2010 and August 2011. Abstinence was the primary outcome. The general population sample and general population-treated samples were derived from Wave 1 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) (n = 43,093). Propensity scores provided a standardized measure of the difference between clinical trial participants and the 2 NESARC samples. The clinical trial was reanalyzed by reweighting the sample with propensity scores derived from the 2 samples to obtain generalizable estimates of treatment effects.

resultsBefore the clinical trial sample was reweighted, the odds ratio (OR) of response to Therapeutic Education System versus treatment as usual in the trial was 1.62 (95% CI, 1.12-2.35). After the sample was reweighted to be representative of the 2 NESARC groups, ORs were 1.33 (95% CI, 0.34-5.26) for the representative sample with any substance use and 1.64 (95% CI, 0.82-3.27) for the representative treated sample.

conclusionsApplying propensity score weighting to clinical trial results provides a method for estimating the population generalizability of clinical trial findings that relies on effect moderators observed in the study sample and population. Broader confidence intervals in the reweighted samples do not necessarily indicate lack of efficacy of the Therapeutic Education System but rather greater uncertainty concerning effectiveness in general population samples.

Indexed as

Illicit DrugsAdolescentAdultAlcoholismFemaleHumansMaleMiddle AgedPropensity ScoreSubstance-Related DisordersTreatment OutcomeYoung AdultIllicit Drugs

Identifiers

PMID28129499
PMCPMC5490656
OpenAlexW2582403541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.